Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit.

Avicenna Journal of Medicine Pub Date : 2022-07-03 eCollection Date: 2022-04-01 DOI:10.1055/s-0042-1750391
Erdal Yavuz, Kasim Turgut, Umut Gulacti, İrfan Aydın, Oguzhan Ozcan, Cihad Sonmez, Ebru Arslan
{"title":"Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit.","authors":"Erdal Yavuz,&nbsp;Kasim Turgut,&nbsp;Umut Gulacti,&nbsp;İrfan Aydın,&nbsp;Oguzhan Ozcan,&nbsp;Cihad Sonmez,&nbsp;Ebru Arslan","doi":"10.1055/s-0042-1750391","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>  Currently, the most effective method in the fight against coronavirus disease 2019 (COVID-19) is vaccination against the disease. However, there are hesitations among society concerning the safety and side effects of COVID-19 vaccines. We aimed to determine the observed side effects that require an emergency room visit after taking the BNT162b2 and CoronaVac vaccines. <b>Methods</b>  This prospective observational study was conducted with patients who presented to the emergency department due to vaccine-related complications after COVID-19 vaccination. The patients' symptoms at the time of presentation, time from vaccination to the onset of symptoms, and dose of the vaccine administered were determined. In addition, the demographic characteristics of the patients, whether they had a history of COVID-19 infection, and their vital signs at the time of presentation were recorded. The variables were compared according to the type of vaccine administered. <b>Results</b>  The study included 182 patients who presented to the emergency department over a 6-month period. It was determined that 166 of these patients (91.2%) had received the BNT162b2 vaccine and 16 (8.8%) had received the CoronaVac vaccine. The majority of the patients did not have a history of COVID-19 infection (70.3%), and most presented to the hospital with complications after the second dose (61%). The onset of vaccine-related symptoms was mostly within 1 to 12 hours (39%). The majority of patients (97.8%) were discharged from the emergency department. The most common symptoms after vaccination were fatigue ( <i>n</i>  = 70), followed by muscle/joint pain ( <i>n</i>  = 52), headache ( <i>n</i>  = 33), and fever ( <i>n</i>  = 32). The rate of dizziness was found to be statistically significantly higher in the CoronaVac vaccine group than in the BNT162b2 vaccine group ( <i>p</i>  = 0.008). There was no statistically significant difference between the two vaccine groups in relation to the remaining symptoms ( <i>p</i>  > 0.005). <b>Conclusion</b>  There were no serious complications related to the BNT162b2 or CoronaVac vaccine. The most common symptom after both vaccines was fatigue; therefore, the BNT162b2 and CoronaVac vaccines can be safely administered.</p>","PeriodicalId":32889,"journal":{"name":"Avicenna Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/8a/10-1055-s-0042-1750391.PMC9272453.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1750391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background  Currently, the most effective method in the fight against coronavirus disease 2019 (COVID-19) is vaccination against the disease. However, there are hesitations among society concerning the safety and side effects of COVID-19 vaccines. We aimed to determine the observed side effects that require an emergency room visit after taking the BNT162b2 and CoronaVac vaccines. Methods  This prospective observational study was conducted with patients who presented to the emergency department due to vaccine-related complications after COVID-19 vaccination. The patients' symptoms at the time of presentation, time from vaccination to the onset of symptoms, and dose of the vaccine administered were determined. In addition, the demographic characteristics of the patients, whether they had a history of COVID-19 infection, and their vital signs at the time of presentation were recorded. The variables were compared according to the type of vaccine administered. Results  The study included 182 patients who presented to the emergency department over a 6-month period. It was determined that 166 of these patients (91.2%) had received the BNT162b2 vaccine and 16 (8.8%) had received the CoronaVac vaccine. The majority of the patients did not have a history of COVID-19 infection (70.3%), and most presented to the hospital with complications after the second dose (61%). The onset of vaccine-related symptoms was mostly within 1 to 12 hours (39%). The majority of patients (97.8%) were discharged from the emergency department. The most common symptoms after vaccination were fatigue ( n  = 70), followed by muscle/joint pain ( n  = 52), headache ( n  = 33), and fever ( n  = 32). The rate of dizziness was found to be statistically significantly higher in the CoronaVac vaccine group than in the BNT162b2 vaccine group ( p  = 0.008). There was no statistically significant difference between the two vaccine groups in relation to the remaining symptoms ( p  > 0.005). Conclusion  There were no serious complications related to the BNT162b2 or CoronaVac vaccine. The most common symptom after both vaccines was fatigue; therefore, the BNT162b2 and CoronaVac vaccines can be safely administered.

Abstract Image

BNT162b2和冠状病毒疫苗相关的副作用需要急诊室就诊。
目前,抗击2019冠状病毒病(COVID-19)最有效的方法是接种疫苗。但是,对于新冠疫苗的安全性和副作用,社会上出现了犹豫。我们的目的是确定服用BNT162b2和CoronaVac疫苗后观察到的需要急诊室就诊的副作用。方法本前瞻性观察研究纳入COVID-19疫苗接种后因疫苗相关并发症就诊的患者。确定患者发病时的症状、从接种疫苗到出现症状的时间以及接种疫苗的剂量。此外,记录患者的人口学特征、是否有COVID-19感染史以及就诊时的生命体征。根据接种的疫苗类型对变量进行比较。结果该研究包括182名在6个月内就诊于急诊科的患者。其中166例(91.2%)接种了BNT162b2疫苗,16例(8.8%)接种了CoronaVac疫苗。大多数患者没有COVID-19感染史(70.3%),大多数患者在第二次注射后出现并发症(61%)。疫苗相关症状大多在1至12小时内出现(39%)。大多数患者(97.8%)从急诊科出院。接种疫苗后最常见的症状是疲劳(n = 70),其次是肌肉/关节疼痛(n = 52),头痛(n = 33)和发烧(n = 32)。CoronaVac疫苗组眩晕发生率明显高于BNT162b2疫苗组(p = 0.008)。两组疫苗的剩余症状无统计学差异(p > 0.005)。结论BNT162b2和CoronaVac疫苗均未出现严重并发症。两种疫苗接种后最常见的症状是疲劳;因此,BNT162b2和冠状病毒疫苗可以安全接种。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
28
审稿时长
26 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信